Xeris Biopharma (XERS) director gets equity grant and 10b5-1 share sale
Rhea-AI Filing Summary
Xeris Biopharma Holdings director John Johnson reported a mix of equity awards and a pre-planned share sale. He received 24,193 shares of common stock through a restricted stock unit grant and 32,996 stock options with a $6.15 exercise price, both vesting in full on the earlier of June 4, 2026 or the company’s next annual stockholder meeting, subject to continued service.
On the same date, he sold 15,000 common shares at a weighted average price of $6.0948 per share under a Rule 10b5-1 trading plan adopted on August 13, 2025. After these transactions, he directly holds 683,083 common shares and 32,996 stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 15,000 shares ($91,422)
Net Sell
3 txns
Insider
JOHNSON JOHN
Role
Director
Sold
15,000 shs ($91K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K |
| Sale | Common Stock | 15,000 | $6.0948 | $91K |
| Grant/Award | Common Stock | 24,193 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,996 shares (Direct);
Common Stock — 683,083 shares (Direct)
Footnotes (1)
- The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Key Figures
RSU shares granted: 24,193 shares
Shares sold: 15,000 shares
Sale price (weighted average): $6.0948 per share
+5 more
8 metrics
RSU shares granted
24,193 shares
Restricted stock unit grant of common stock
Shares sold
15,000 shares
Open-market sale of common stock
Sale price (weighted average)
$6.0948 per share
Weighted average sale price for 15,000 shares
Options granted
32,996 options
Stock options on common stock granted
Option exercise price
$6.15 per share
Stock option conversion or exercise price
Option expiration
June 4, 2036
Expiration date of granted stock options
Common shares held after
683,083 shares
Direct common stock holdings after transactions
Options held after
32,996 options
Direct option holdings after transactions
Key Terms
Rule 10b5-1 trading plan, restricted stock unit, weighted average price, 2018 Stock Option and Incentive Plan, +1 more
5 terms
Rule 10b5-1 trading plan financial
"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock unit financial
"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan")."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
2018 Stock Option and Incentive Plan financial
"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan")."
vest in full financial
"These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Xeris Biopharma (XERS) director John Johnson report?
John Johnson reported receiving restricted stock units and stock options, plus selling shares. He was granted 24,193 common shares, 32,996 options at $6.15, and sold 15,000 shares at a weighted average $6.0948 on the same date.
What equity awards did John Johnson receive from Xeris Biopharma (XERS)?
John Johnson received 24,193 common shares via a restricted stock unit grant and 32,996 stock options. The options carry a $6.15 exercise price and both the RSUs and options vest in full upon the earlier of June 4, 2026 or the next annual meeting.
When will John Johnson’s new Xeris Biopharma (XERS) RSUs and options vest?
Both the 24,193 restricted stock units and 32,996 stock options vest in full upon the earlier of June 4, 2026 or the date of Xeris Biopharma’s next annual stockholder meeting, provided John Johnson continues his service through that vesting date.